Single-tube liquid biopsy overcomes tissue biopsy failure to give oncologist personalized treatment decision guidance in matter of days.
A southeastern oncologist treating a 66-year-old male with lung cancer was unable to obtain testing results due to the failure of the tissue biopsy from the tumor. The oncologist referred a blood sample to CIRCULOGENE for its expertise in personalized cancer testing. In less than a week, CIRCULOGENE was able to detect a genetic alteration and match the patient’s cancer with a specific therapeutic.
Using a single tube of blood, CIRCULOGENE’s technology tested for genetic alterations for four different applications, which indicate different treatment strategies:
- DNA Mutations
- RNA Fusions
- PD-L1 Expression
- MSI (microsatellite instability)
In under one week, CIRCULOGENE detected a PD-L1 expression greater than 50% and identified 47 ongoing trials for DNA mutations associated with this lung cancer. The oncologist immediately initiated pembrolizumab therapy for his patient.
“It is unclear what the original treatment decision would have been due to the lack of a tissue biopsy; however, using a single tube of blood, CIRCULOGENE provided personalized results, allowing the treating physician to get the patient on the right therapy in a matter of days, instead of weeks or months.”– Chen Yeh, Chief Scientific Officer